Key insights of the Clinical Practice Guidelines for the Management of Hypertension in China

Abstract

In September 2024, 3 leading committees—the Chinese Society of Cardiology under the Chinese Medical Association, the Hypertension Committee of the Cross-Straits Medicine Exchange Association, and the Cardiovascular Disease Prevention and Rehabilitation Committee of the Chinese Association of Rehabilitation Medicine—jointly released the Clinical Practice Guidelines for the Management of Hypertension in China (hereinafter referred to as the “Guidelines”). These Guidelines address 44 key clinical issues closely related to the prevention and management of hypertension, offering a total of 98 evidence-based recommendations. This article highlights and provides an in-depth analysis of the 9 key insights from the Guidelines to assist physicians in better understanding its most critical content.

Keywords

guidelines / hypertension / key insights

References

[1] Chinese Society of Cardiology , Chinese Medical Association ; Hypertension Committee of Cross-Straits Medicine Exchange Association ; Cardiovascular Disease Prevention and Rehabilitation Committee , Chinese Association of Rehabilitation Medicine . Clinical Practice Guidelines for the management of hypertension in China. Zhonghua Xin Xue Guan Bing Za Zhi. 2024; 52: 985- 1032.

[2] McEvoy JW , McCarthy CP , Bruno RM , et al.; ESC Scientific Document Group. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45: 3912- 4018.

[3] Whelton PK , Carey RM . The 2017 clinical practice guideline for high blood pressure. JAMA. 2017; 318: 2073- 4.

[4] Kario K , Okura A , Hoshide S , Mogi M . The WHO Global Report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024; 47: 1099- 102.

[5] Cao X , Zhao Z , Kang Y , et al.; China Burden of Disease Attributable to Risk Factors Collaborative Group. The burden of cardiovascular disease attributable to high systolic blood pressure across China, 2005-18: a population-based study. Lancet Public Health. 2022; 7: e1027- 40.

[6] Qi Y , Han X , Zhao D , et al. Long-term cardiovascular risk associated with stage 1 hypertension defined by the 2017 ACC/AHA hypertension guideline. J Am Coll Cardiol. 2018; 72: 1201- 10.

[7] Chinese Society of Cardiology of Chinese Medical Association ; Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine ; Cardiovascular Disease Committee of Chinese Association of Gerontology and Geriatrics ; Thrombosis Prevention and Treatment Committee of Chinese Medical Doctor Association . Chinese guideline on the primary prevention of cardiovascular diseases. Zhonghua Xin Xue Guan Bing Za Zhi. 2020; 48: 1000- 38.

[8] Li J , Zhao D , Cai J , Chen S , Wu S , Qi Y . Cost-effectiveness of treatment in adults with blood pressure of 130-139/80-89 mmHg and high cardiovascular risk in China: a modelling study. Lancet Reg Health West Pac. 2024; 42: 100962.

[9] Blood Pressure Lowering Treatment Trialists' Collaboration . Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021; 397: 1625- 36.

[10] Sun Y , Mu J , Wang DW , et al.; CRHCP Study Group. A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial. Lancet. 2022; 399: 1964- 75.

[11] Zhang W , Zhang S , Deng Y , et al.; STEP Study Group. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021; 385: 1268- 79.

[12] Wei J , Galaviz KI , Kowalski AJ , et al. Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis. JAMA Netw Open. 2020; 3: e1921618.

[13] Wright JM , Musini VM , Gill R . First-line drugs for hypertension. Cochrane Database Syst Rev. 2018; 4: CD001841.

[14] Poole-Wilson PA , Lubsen J , Kirwan BA , et al.; Coronary disease Trial Investigating Outcome With Nifedipine Gastrointestinal Therapeutic System Investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004; 364: 849- 57.

[15] Yndigegn T , Lindahl B , Mars K , et al.; REDUCE-AMI Investigators. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med. 2024; 390: 1372- 81.

[16] Zheng C , Dai H , Huang J , et al. The efficacy and safety of sacubitril/valsartan in the treatment of chronic heart failure: a meta-analysis. Am J Transl Res. 2021; 13: 12114- 28.

[17] Palmer SC , Tendal B , Mustafa RA , et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021; 372: m4573.

[18] Krishnamoorthy Y , Nagarajan R , Murali S . Effectiveness of multiple combined lifestyle interventions in reducing blood pressure among patients with prehypertension and hypertension: a network meta-analysis. J Public Health (Oxf). 2023; 45: e319- 31.

[19] Yuan Y , Jin A , Neal B , et al. Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial. Nat Med. 2023; 29: 973- 81.

[20] Barbato E , Azizi M , Schmieder RE , et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023; 44: 1313- 30.

[21] Mancia G , Kreutz R , Brunström M , et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023; 41: 1874- 2071.

[22] Käyser SC , Dekkers T , Groenewoud HJ , et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016; 101: 2826- 35.

RIGHTS & PERMISSIONS

by the Authors, published by Wolters Kluwer Health, Inc. on behalf of Higher Education Press.